1/11 HD - DKFZ. Deutsches Krebsforschungszentrum German Cancer Research Center. Heidelberg. Nov Technology Transfer 1

Transcription

1 1/11 HD - DKFZ Deutsches Krebsforschungszentrum German Cancer Research Center Heidelberg Nov Technology Transfer 1

2 3/11 Bioshuttle Technology Modular Delivery System for Macromolecules into Compartments of Living Cells contributing departments of DKFZ: - Clinical Cooperation Unit Radiation Oncology - Biological Strategies Group - Central Section for Peptide Synthesis - Division Biophysics for Macromolecules - Division Organisation of Complex Genomes Nov Technology Transfer 2

3 4/11 Bioshuttle modular structure of this transport carrier Cytoplasmic Import Module -S S- Nuclear Localisation Sequence (NLS) Spacer Substance Transport Peptide: Seq: RQIKIWFQNRRMKWK Rhodamine110-labeled Address Peptide: Seq: PKKKRKV NLS-SV40T SV40T antigen Substance labeled (DNA, PNA, antibody, protein, drug) Nov Technology Transfer 3

4 5/11 The Disulfide Bond of Bioshuttle cleavage makes a nuclear import signal accessible without Cleavage Alexa (L)-TP-(L)-NLS-KK cytoplasm KK (Rhod110) Peptide (Rhod110) -Peptide with Cleavage at S S- Alexa (L)-TP TP-S S-(L) (L)-NLS-KK KK (Rhod110) Peptide (Rhod110) -Peptide cytoplasm nucleus Nov Technology Transfer 4

5 6/11 Nuclear Directed Transport Cytopl.. IM Cytopl.. IM outside cell cytoplasm nucleus Nov Technology Transfer 5

6 7/11 Bioshuttle Mediated DNA-Delivery a highly efficient transport system cell line: AT-1 final conc.: 100 pm dsdna 2000 bp Rhodamine 110 incubation time: Nov Technology Transfer 6

7 Bioshuttle ioshuttle Gene mediated Transfer Gene-Delivery Efficiency GFP + DIC 'Bioshuttle - Quick - Protocol' (3 step) pdna Peptide/ Gene + 'Bioshuttle -Kit DU145 cells 1 Hybridization blue: nucleus DAPI-staining; green: GFP-Protein cytoplasma located Conjugat. / Bioshuttle GFP + DIC 2 Application 3 Activation AT1 cells Protein incubat. time: 1h; ratio GFP-cells: total cell no. Nov Technology Transfer 7

8 Bioshuttle mediated Drug-Delivery Delivery in BNCT Cell distribution of the intact HeLa-S cells [%] viable Semi-viable dead 24h I 'Bioshuttle'-p-BPA BPA 10 + Neutron Irradiation II Neutron Irradiation III 'Bioshuttle'-p-BPA 10 without irradiation IV untreated Control h I 'Bioshuttle'-p-BPA BPA 10 + Neutron Irradiation II Neutron Irradiation III 'Bioshuttle'-p-BPA 10 without irradiation IV untreated Control h I 'Bioshuttle'-p-BPA BPA 10 + Neutron Irradiation II Neutron Irradiation Molecular Modeling 79.2 Group, C.W. 4.6 von der Lieth 16. III 'Bioshuttle'-p-BPA 10 without irradiation IV untreated Control Nov Technology Transfer 8

9 Anti-Gene Gene Strategy Chronical Myeloic Leucemia Nov Technology Transfer 9

10 Chromosomal Rekombination Lokus - K562 c-bcr-bereich - Chr 22 b2b3 (HUSAR; SRS) GTGGTGTGAA TCCACTTGTC CTAATAGACC ACTCCAACTT TCTGAACATC CCAGGCTTTC 60 CTGGTACAGT CCCCATCTTC CAGCCAAGAG GAGAGCATGG CTCAGGTGGG ATTCAGGCGA 120 GAACAGGGCA ACGCACACCT ACTAGCCAAG ATACAAAGCA CTTAATACAG GGAGGAGTCA 180 TGTGGGCAGA GCCAGTGGGT CTGGGTTCCC CTCATGAGGA CCGAGAGGGG ACCAACACCT 240 GTTAGATGTC TGCTGTGTTC CTGACGTTGG CCTGGGTGTG GGATGTGACT GGGTGTCTGT 300 TGCTCTCCTT GGCAGGTGCC TGCCCTGGAG GTAAAGAGGC TGGGACAGTA 350 c-abl-bereich - Chr 9 a1a2 GTGAGAGGTC CAAATTATGC AATTTTCTTT TAAAATAAAT GCAGTTTTAT TACTTTCCAC 180 TTGTAGCCAT TATAGGCAGT AGATTAAATG AGTTTCTAGA GAAACCTCCT TTAAAAATAA 240 AGTTATTTAA TTAGTCCAAG GTTTAAATAT TTCCCCTGGA ATCTTTTACA TGACAATGTC 300 TTAGCCAGAC AATTTTTAAG AAACAAAATT CTCCATCCTA ACTCCTATCC CCATCAACAG 360 TCCAAATCTT AACCTTTCTT TTTTTTTTTT TAGACAGAGT CGAGCTCTGT TGCCCAGGCT 420 GGAGCGTGGT GATGCAATCT TGGCTCACTG CAACCTCCAC CTTCCGGGTT CAAGCGAAAC 480 CCCTGCCTCA GCCTCCCGAG TAGCTGGGAC TGCAG 515 bcr/abl t (22q11; 9q34) GTGGTGTGAA TCCACTTGTC CTAATAGACC ACTCCAACTT TCTGAACATC CCAGGCTTTC 60 CTGGTACAGT CCCCATCTTC CAGCCAAGAG GAGAGCATGG CTCAGGTGGG ATTCAGGCGA 120 GAACAGGGCA ACGCACACCT ACTA TAAG AAACAAAATT CTCCATCCTA ACTCCTATCC CCATCAACAG 360 TCCAAATCTT AACCTTTCTT TTTTTTTTTT TAGACAGAGT CGAGCTCTGT TGCCCAGGCT 420 GGAGCGTGGT GATGCAATCT TGGCTCACTG CAACCTCCAC CTTCCGGGTT CAAGCGAAAC 480 Nov Technology Transfer 10

11 Anti Gene Rek.Lok./K562 - Strategy Proliferation Test Genom. Targetbereich bcr/abl + unbeh. Kontrolle GA GAACAGGGCA PNA ACGCACACCT ACTAAG AAACAAAATT CTCCATCCTA Anti Gen - Rhod110 (L)-TP-S-S-(L)-NLS-KK (Rhod110) -PNA Random (L)-TP-S-S-(L)-NLS-KK (Rhod110) -PNA Anti Gen bcr/abl AG PNA bcr/abl Zellzahl * Proliferation K562 TGCGTGTGGA TGATTC TTTGTTTTAA NS PNA RANDOM GTACTTTTAT CGGCAT CGATACGCTA [h] Nov Technology Transfer 11

12 Applications of Bioshuttle - Diagnostics A) Delivery of DNA-Plasmid Modul:TPU -S-H H-S- Address * -K-K-PNA-Clamp DNA-Plasmid B) Delivery of Peptide Fragments Modul:TPU -S-H H-S- Address * -K-K-Succinimide Peptide Fragment Address * : NLS, MLS, ER Nov Technology Transfer 12

13 Bioshuttle mediated Drug-Delivery Delivery in MRI Molecular Modeling Group, C.W. von der Lieth Nov Technology Transfer 13

14 Bioshuttle mediated Drug-Delivery Delivery in MRI MR signal intensity [SI] HeLa [hours] Lymphocytes increase in signal intensity decrease in signal intensity Nov Technology Transfer 14

15 8/11 Commercial Opportunity Diagnostics Therapeutics in vivo detection of specific therapy on proteins of interest gene and protein level Molecular Imaging (MRI, PET, SPECT) Nov Technology Transfer 15

16 9/11 Applications of Bioshuttle proof of principle with tissue cells / animal studies 1. Bioshuttle mediated (DNA)-antisense and gene directed strategies for: a) Chronic Myelogenous Leukemia (CML) therapy; [BCR-ABL] b) Cervix cancer (HPV) therapy c) antibiotic resistant bacteria (e.g. addressing lactamase or tetracycline resistance gene) 2. Bioshuttle mediated gene transfer and targeted gene activation e.g. shown with reporter genes intracellular activated by focussed ultrasound 3. Simultaneously therapy and monitoring for molecular imaging e.g. intracellular Neutron Capture Therapy MR controlled Nov Technology Transfer 16

17 10/11 Advantages of Bioshuttle Variable due to modular structure Rapid and efficient uptake without membrane perturbing Site specific targeting/retention of macromolecules using immanent cellular mechanism e.g. nuclear transport No toxicity was observed in animal studies up to molarities of 100 nm Efficient delivery in monolayer and suspension cells Applicable to various targets: e.g. antisense DNA, PNA, antibodies, macromolecular drugs, peptide Selective delivery in eucaryotic or procaryotic cells (bacteria) Nov Technology Transfer 17

18 11/11 Bioshuttle Technology Contact Person: Dr. Frieder Kern, Office of Technology Transfer phone: +49-(0) ; fax: +49-(0) Principal Investigators and Inventors: Dr. K. Braun, Dr. R. Pipkorn, Dr. W. Waldeck, Prof. Dr. J. Debus Published Patent Families: WO 01/05432; WO 03/039438; WO 03/059392; WO 03/006065; WO 03/040175; WO 03/ and WO 2004/050698; patents pending. Nov Technology Transfer 18

19 Scientific publications (to be continued): 1. Braun K. et al. : J. Mol. Biol. 2002, Vol. 318: : A Biological Transporter for the Delivery of Peptide Nucleic Acids (PNAs) to the Nuclear Compartment of Living Cells. 2. Krüger R, Braun K, Pipkorn R, Lehmann WD. Characterization of a gadolinium-tagged modular contrast agent by element and molecular mass spectrometry, J Analyt Atomic Spectrometry 19, Pipkorn R, Waldeck W, Braun K, Synthesis and application of functional peptides as cell nucleus-directed molecules in the treatment of malignant diseases, J Mol Recognit. 16: 240-7, Braun K, Wolber G, Waldeck W, Pipkorn R, Jenne J, Rastert R, Ehemann V, Eisenmenger A, Corban-Wilhelm H, Braun I, Heckl S, Debus J. The Enhancement of Neutron Irradiation of HeLa-S Cervix Carcinoma Cells by Cell-Nucleus-addressed Deca-p-Boronophenylalanine, Eur J Med Chem. 38: , 2003 Nov Technology Transfer 19

20 Scientific publications (continued): 5. Heckl S, Debus J, Jenne J, Pipkorn R, Waldeck W, Spring H, Rastert R, von der Lieth CW, Braun K. CNN-Gd enables Cell Nucleus Molecular Imaging of Prostate Cancer Cells - the last 600 nm-, Cancer Res. 62: , Heckl S, Pipkorn R, Waldeck W, Spring H, Jenne J, von der Lieth CW, Corban-Wilhelm H, Debus J, Braun K. Intracellular Visualization of Prostate Cancer using Magnetic Resonance Imaging, Cancer Res. 63: , Heckl S, Braun K, Debus J, Molecular Imaging. A Future Diagnostic Method in Neurooncology? TumorDiagnostik und Therapie 23: , Braun K, Ehemann V, Waldeck W, Pipkorn R, Corban-Wilhelm H, Jenne J, Gissmann L, Debus J. HPV18 E6 and E7 Genes affect Cell Cycle, prb and p53 of Cervical Tumor Cells and represent prominent Candidates for Intervention by Use Peptide Nucleic Acids (PNAs), Cancer Lett. 209: 37-49, 2004 Nov Technology Transfer 20